Other: eculizumab (DrugBank: Eculizumab)
8 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
11 | 重症筋無力症 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
14 | 慢性炎症性脱髄性多発神経炎/多巣性運動ニューロパチー | 0 |
61 | 自己免疫性溶血性貧血 | 0 |
62 | 発作性夜間ヘモグロビン尿症 | 0 |
109 | 非典型溶血性尿毒症症候群 | 1 |
222 | 一次性ネフローゼ症候群 | 0 |
223 | 一次性膜性増殖性糸球体腎炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02614898 (ClinicalTrials.gov) | November 4, 2015 | 24/11/2015 | Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment | Evidence - Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment | Atypical Hemolytic Uremic Syndrome | Other: Eculizumab | Alexion Pharmaceuticals | NULL | Terminated | N/A | N/A | All | 67 | United States;Australia;Germany;United Kingdom |